Present across all 7 projects spanning wildly different technical domains, consistent with a cross-cutting dissemination and innovation brokering role.
REDINN - SRL
Italian innovation SME specializing in EU project dissemination, researcher mobility, and knowledge transfer across energy, health, and bio-based product domains.
Their core work
REDINN (Rete Europea dell'Innovazione) is an Italian SME that acts as an innovation intermediary and dissemination partner in EU research consortia. Their core work involves facilitating knowledge transfer, researcher mobility, and translating research outputs into market-relevant formats across diverse scientific domains. With four MSCA-RISE projects in their portfolio, they specialize in bridging research institutions and industry through structured exchange programs. Their involvement spans topics from energy transition to selenium-based therapies, indicating a role focused on innovation management rather than deep technical research in any single domain.
What they specialise in
Four MSCA-RISE projects (CLUSDEV MED, NEOSETAC, Se4All, OXIPRO) focused on international researcher exchange between academia and industry.
Involved in NEOSETAC (selenium-based cancer nanocapsules) and Se4All (selenium-biofortified dairy products), suggesting a growing niche in selenium value chains.
Early projects BlueSCities, ENTRUST, and ALICE addressed smart cities, energy transition, and urban wastewater management.
OXIPRO (2021-2025) focuses on oxidoreductase-based replacements in textiles, nutraceuticals, detergents, and cosmetics.
How they've shifted over time
REDINN's early H2020 activity (2015-2019) centered on urban sustainability themes — smart cities integration, energy system transitions, cluster development, and wastewater innovation. From 2018 onward, their portfolio pivoted sharply toward life sciences and bio-based applications, particularly selenium chemistry applied to both health (breast cancer nanocapsules) and food (biofortified dairy). Their most recent projects (2021-2025) show a consolidation around bio-based consumer products and functional foods, suggesting the organization followed the EU funding landscape toward green chemistry and circular economy topics.
REDINN is moving toward bio-based and circular economy applications, making them a relevant dissemination partner for projects in green chemistry, functional foods, and sustainable consumer products.
How they like to work
REDINN operates exclusively as a consortium participant — they have never coordinated an H2020 project, which is consistent with their role as a support partner for dissemination and innovation management. With 65 unique partners across 20 countries, they maintain an exceptionally broad network relative to their project count, reflecting a connector organization that brings reach rather than deep technical capacity. Their diverse consortium exposure makes them easy to integrate into new projects, though partners should expect a facilitation role rather than technical leadership.
REDINN has built a wide network of 65 partners across 20 countries through just 7 projects, averaging over 9 unique partners per project. This pan-European reach, operated from a base near Rome, positions them as a well-connected intermediary with contacts across most EU member states.
What sets them apart
REDINN's value lies in being a versatile dissemination and innovation transfer partner that can plug into almost any research domain. Unlike technically specialized SMEs, they bring communication infrastructure, network access, and experience managing knowledge exchange across academic-industry boundaries. For consortium builders, they fill the increasingly important "impact and exploitation" work package without requiring deep onboarding into the science.
Highlights from their portfolio
- ENTRUSTTheir largest funded project (EUR 331,156), focused on energy system transition through education and skills development — demonstrates capacity for substantial dissemination work packages.
- NEOSETACAn unusual topic for an innovation consultancy — selenium-based nanocapsules for breast cancer treatment — signaling their ability to operate in advanced biomedical research contexts.
- OXIPROTheir second-largest project (EUR 235,000) and most recent, covering circular economy applications across textiles, cosmetics, and detergents — indicates their current strategic direction.